[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 11, 1996

The Heritage of Hepatitis B Vaccine

Author Affiliations

From the Merck Vaccine Division, Merck & Co Inc, Whitehouse Station, NJ.

JAMA. 1996;276(22):1796-1798. doi:10.1001/jama.1996.03540220020011
Abstract

Pioneering development of the plasma-derived and yeast-derived recombinant hepatitis B vaccines represents a major contribution to preventive health care of this century. Current and expanding worldwide application of hepatitis B vaccine promises to eliminate and eventually eradicate hepatitis B infection from the human population and, with it, many cases of cirrhosis and cancer of the liver.

×